Global & Disaster Medicine

Two potential drugs have shown a survival rate of as much as 90% in a clinical trial in the Democratic Republic of Congo (DRC).

The Sun

“…..The experimental treatments – REGN-EB3 and a monoclonal antibody called mAb114 – were both developed using antibodies from Ebola survivors.

They are now going to be offered to all patients in the DRC, according to US National Institute of Allergy and Infectious Diseases…..”


“……The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the V920 Ebola Zaire vaccine (Ervebo, Merck ), the first vaccine to protect against the Ebola virus disease caused by Zaire Ebola virus in at-risk adults aged 18 years or older…..”

Comments are closed.


Recent Posts